Early Phase 2 Clinical Study of JTS-661 - Efficacy and Safety Study -
Latest Information Update: 04 Jan 2021
At a glance
- Drugs Serlopitant (Primary)
- Indications Pruritus
- Focus Adverse reactions; Therapeutic Use
- Sponsors Japan Tobacco
- 09 May 2018 Status changed from active, no longer recruiting to discontinued.
- 27 Apr 2018 Status changed from recruiting to active, no longer recruiting.
- 06 Feb 2018 New trial record